Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cance

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of Urology

• Publication date

  1992-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(17)36577-1PMID 1635122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current status of intravesical chemotherapy trials in the EORTC Urological Group. An Overview

  2004cited by this paper
• Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.

  1989cited by this paper
• Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.

  1989cited by this paper
• Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.

  1989cited by this paper
• Quelle chimiothérapie intravésicale pour quelle tumeur de vessie

  1988cited by this paper
• [Which intravesical chemotherapy for what tumor of the bladder?].

  1988cited by this paper
• Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.

  1988cited by this paper
• BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.

  1988cited by this paper
• Statistical analysis techniques and sample size determination for clinical trials of treatments for bladder cancer.

  1986cited by this paper
• Does intravesical chemotherapy prevent invasive bladder cancer?

  1984cited by this paper
• Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.

  1984cited by this paper
• Anaphylactic reactions to repeated intravesical instillation with cisplatin.

  1983cited by this paper
• Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.

  1982cited by this paper
• Intravesical Chemoprophylaxis of Superficial Bladder Cancer

  1982cited by this paper
• The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder.

  1981cited by this paper
• Letter: Potential variants of phenylketonuria.

  1975cited by this paper

• Association between tumor size and prognosis in bladder cancer: novel classifications and insights from a SEER database analysis

  2024cites this paper
• A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases.

  2018cites this paper
• Nichtinvasives Harnblasenkarzinom

  2017cites this paper
• Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model

  2017cites this paper
• Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

  2015cites this paper
• In vitro and in vivo experiments on electrochemotherapy for bladder cancer.

  2015cites this paper
• Frailty multi-state models for the analysis of survival data from multicenter clinical trials

  2013influential citation
• Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non‐muscle‐invasive bladder tumour

  2013cites this paper
• The EORTC Genito-Urinary Cancers Group: 35 years of achievements and future strategy

  2012cites this paper
• The EORTC Genito-Urinary Cancers Group: 35 years of achievements and future strategy

  2012cites this paper
• A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.

  2012cites this paper
• Continuous covariate frailty models for censored and truncated clustered data

  2012cites this paper
• External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

  2011cites this paper
• Management of BCG failures in non-muscle-invasive bladder cancer

  2009cites this paper
• Validation of prognostic indices using the frailty model

  2009cites this paper
• Paclitaxel and cisplatin as intravesical agents against non‐muscle‐invasive bladder cancer

  2008cites this paper
• The management of superficial bladder cancer

  2007cites this paper
• Comparison of different estimation procedures for proportional hazards model with random effects

  2007cites this paper
• Advances in the management of superficial bladder cancer.

  2007cites this paper
• Superficial bladder cancer: part 2. Management.

  2007cites this paper
• Prognostic Factors in Non–Muscle-Invasive Bladder Tumors: I. Clinical Prognostic Factors: A Review of the Experience of the EORTC Genito-Urinary Group II. Biologic Prognostic Markers

  2007cites this paper
• Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder

  2006cites this paper
• Bladder Cancer Predicting Recurrence and Progression in Individual Patients with Stage Ta T 1 Bladder Cancer Using EORTC Risk Tables : A Combined Analysis of 2596 Patients from Seven EORTC Trials

  2006cites this paper
• Treatment options for BCG failures

  2006cites this paper
• Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

  2006cites this paper
• Bladder Perforation: A Potential Risk of Early Endovesical Chemotherapy with Mitomycin C

  2005cites this paper
• A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model

  2005cites this paper
• Intravesical Doxorubicin for Superficial Bladder Carcinoma

  2005cites this paper
• Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial

  2004cites this paper
• Intravesical gemcitabine: a phase 1 and pharmacokinetic study.

  2004cites this paper
• Denovo urothelial carcinoma of the upper and lower urinary tract in kidney — transplant patients with end-stage analgesic nephropathy

  2004cites this paper
• Advances in intravesical therapy of urinary bladder cancer

  2004cites this paper
• Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer

  2004cites this paper
• Intravesical therapy of superficial bladder cancer.

  2003cites this paper
• Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma.

  2002cites this paper
• Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.

  2002cites this paper
• Intravesical Chemotherapy in the Treatment of Superficial Bladder Cancer

  2001cites this paper
• Diagnosis and management of superficial bladder cancer.

  2001cites this paper
• Treatment of Superficial Bladder Tumors: Achievements and Needs

  2000cites this paper
• An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.

  2000cites this paper
• [Place of chemotherapy in the treatment of invasive bladder tumors].

  1999cites this paper
• T1 GIII Bladder Cancer

  1999cites this paper
• Intravesical Drug Delivery

  1999cites this paper
• Clinical pharmacology of anticancer agents in relation to formulations and administration routes.

  1999cites this paper
• Treatment of Ta, T1 Bladder Tumors: Recent Results of the EORTC-GU Group

  1998cites this paper
• Role of P-glycoprotein in chemoresistant superficial bladder tumours.

  1997cites this paper
• Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives.

  1997cites this paper
• Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.

  1997cites this paper
• Therapie und Rezidivprophylaxe beim oberflächlichen Harnblasenkarzinom

  1997cites this paper
• A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer

  1996cites this paper
• Quality of life in patients undergoing bacille Calmette-Guérin therapy for superficial bladder cancer.

  1996cites this paper
• Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.

  1996cites this paper
• A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.

  1996cites this paper
• Factors affecting recurrence and progression in superficial bladder tumours.

  1995cites this paper
• INTRAVESICAL ANTITUMOR THERAPY IMMEDIATELY AFTER TRANSURETHRAL RESECTION OF BLADDER CANCER

  1994cites this paper
• Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

  1993cites this paper